Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

PARP inhibitor

- PMLiVE

CHMP backs Lynparza in breast cancer, Dupixent in asthma

Akcea's FDA-rejected Waylivra also recommended

- PMLiVE

Lynparza scores against pancreatic cancer

AZ and MSD drug success in BRCA-mutated disease

- PMLiVE

Cancer drugs and China sustain AZ’s return to growth

Tagrisso set to become biggest seller

- PMLiVE

AZ’s Sean Bohen to exit after business overhaul; report

Recent departures raises concern among analysts

- PMLiVE

AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief

Underlines importance of cancer drugs to company's future growth

- PMLiVE

AstraZeneca wins NICE backing for asthma injection

NICE hails 'competitive pharma market'

- PMLiVE

First-line ovarian approval cements AZ’s Lynparza lead

Also new data on recently approved kidney disease drug

- PMLiVE

China first market to approve AZ’s kidney drug roxadustat

A milestone for China and AZ and partners FibroGen

- PMLiVE

AZ still sees route to approval for Imfinzi in MYSTIC trial

New analysis shows opportunity in NSCLC

- PMLiVE

Is AstraZeneca looking for its next CEO?

Shareholders said to want succession plan in place

- PMLiVE

AZ drug matched to cancer mutation passes phase 2 test

More data from promising class of targeted small molecule drugs

- PMLiVE

AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi

AZ continues sell-off, SOBI spies US expansion

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links